PriceTargets.com logo

LON:MXC - MGC Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 7.20
  • Forecasted Upside: 700.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 0.90 As of 06/30/2022 01:00 AM ET
+0.30 (1.20%)

This chart shows the closing price for MXC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MGC Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MXC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MXC

Analyst Price Target is GBX 7.20
▲ +700.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MGC Pharmaceuticals in the last 3 months. The average price target is GBX 7.20, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 700.00% upside from the last price of GBX 0.90.

This chart shows the closing price for MXC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in MGC Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/5/2022Canaccord Genuity GroupReiterated RatingSpeculative BuyGBX 7.20
1/5/2022Canaccord Genuity GroupLower Price TargetSpeculative BuyGBX 8 ➝ GBX 7.20
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

MGC Pharmaceuticals logo
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
Read More

Today's Range

Now: GBX 0.90
Low: 0.86
High: 0.95

50 Day Range

MA: GBX 1.10
Low: 0.90
High: 1.35

52 Week Range

Now: GBX 0.90
Low: 0.85
High: 3.95

Volume

3,157,880 shs

Average Volume

4,114,168 shs

Market Capitalization

£24.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MGC Pharmaceuticals?

The following equities research analysts have issued research reports on MGC Pharmaceuticals in the last twelve months: Canaccord Genuity Group Inc..
View the latest analyst ratings for MXC.

What is the current price target for MGC Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for MGC Pharmaceuticals in the last year. Their average twelve-month price target is GBX 7.20, suggesting a possible upside of 700.0%.
View the latest price targets for MXC.

What is the current consensus analyst rating for MGC Pharmaceuticals?

MGC Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MXC will outperform the market and that investors should add to their positions of MGC Pharmaceuticals.
View the latest ratings for MXC.

How do I contact MGC Pharmaceuticals' investor relations team?

MGC Pharmaceuticals' physical mailing address is 415 W Wall St Ste 475, Midland, Texas 79701-4482. The company's listed phone number is 19156821119. The official website for MGC Pharmaceuticals is www.mexcoenergy.com. Learn More about contacing MGC Pharmaceuticals investor relations.